| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/02/2000 | US6057445 Formation of carbon nitrogen bond, cyclization and halogenation |
| 05/02/2000 | US6057441 Cardiovascular disorders and gastrointestinal disorders |
| 05/02/2000 | US6057440 Process for preparing bis-indoly macrocycles |
| 05/02/2000 | US6057369 Use in the treatment of disease states associated with proteins that mediate cellular activity which are capable of being modulated by inhibiting a matrix metalloproteinase (mmp), tumor necrosis factor (tnf) or cyclic amp |
| 05/02/2000 | US6057364 Fluoro-substituted adamantane derivatives |
| 05/02/2000 | US6057349 2-imidazoline, 2-oxazoline, 2-thiazoline, and 4-imidazole derivatives of methylphenyl, methoxphenyl, and aminophenyl alkylsulfonamides and ureas and their use |
| 05/02/2000 | US6057345 Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists |
| 05/02/2000 | US6057338 Useful in the treatment of diabetes, cancer, acromegaly, restenosis, depression, irritable bowel syndrome, pain and diabetic retinopathy |
| 05/02/2000 | US6057336 Lactam metalloprotease inhibitors |
| 05/02/2000 | US6057332 Substituted 1,4-dihydropyrimidine-5-carboxylate compounds, their preparation and uses |
| 05/02/2000 | US6057326 Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors |
| 05/02/2000 | US6057325 Have central dopamine and serotonin antogonistic activity |
| 05/02/2000 | US6057321 1,4-diazabicyclo [2.2.2] oct-2-ylmethyl derivatives, their preparation and therapeutic application |
| 05/02/2000 | US6057317 Heterocyclic compounds |
| 05/02/2000 | US6057301 Moisture resistant, improved storage stability |
| 05/02/2000 | US6057294 Peptide |
| 05/02/2000 | US6057124 Nucleic acids encoding ligands for HEK4 receptors |
| 05/02/2000 | US6055936 Sea cucumber carotenoid lipid fractions and process |
| 05/02/2000 | CA2069961C Method and compositions for inhibition of disorders associated with oxidative damage |
| 05/02/2000 | CA2022740C Cyclic neurokinin a antagonists |
| 04/27/2000 | WO2000023587A2 Gene therapy of alzheimer's disease by delivery of an encoded apolipoprotein e |
| 04/27/2000 | WO2000023572A1 Tnfr related gene 12 |
| 04/27/2000 | WO2000023571A2 A method for isolating and purifying oligodendrocytes and oligodendrocyte progenitor cells |
| 04/27/2000 | WO2000023457A1 Adenine derivatives |
| 04/27/2000 | WO2000023445A1 New compounds, their preparation and use |
| 04/27/2000 | WO2000023444A1 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds |
| 04/27/2000 | WO2000023441A1 3-tetrahydropyridin-4-yl indoles for treatment of psychotic disorders |
| 04/27/2000 | WO2000023438A1 N-(imidazolylalkyl)substituted cyclic amines as histamine-h3 agonists or antagonists |
| 04/27/2000 | WO2000023426A1 Novel imidazoles with anti-inflammatory activity |
| 04/27/2000 | WO2000023425A1 New compounds, their preparation and use |
| 04/27/2000 | WO2000023424A1 Epibatidine analogues as acetylcholine receptor antagonists |
| 04/27/2000 | WO2000023421A1 (SUBSTITUTED)ACYL DIPEPTIDYL INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES |
| 04/27/2000 | WO2000023417A1 New compounds, their preparation and use |
| 04/27/2000 | WO2000023416A1 New compounds, their preparation and use |
| 04/27/2000 | WO2000023415A1 New compounds, their preparation and use |
| 04/27/2000 | WO2000023407A2 Ureido-thiobutyric acid derivatives as ppar-agonists |
| 04/27/2000 | WO2000023102A1 Method for regulating the permeability of the blood brain barrier |
| 04/27/2000 | WO2000023092A1 Contulakin-g, analogs thereof and uses therefor |
| 04/27/2000 | WO2000023091A2 Specific therapeutic interventions obtained by interference with redistribution and/or targeting of cyclic nucleotide phosphodiesterases of i-kappa-b kinases |
| 04/27/2000 | WO2000023089A1 Natural formulation for the treatment and prevention of depression, containing st john's wort and derivatives of dihydro- and tetrahydrofolic acid |
| 04/27/2000 | WO2000023080A1 IMPROVING MEMORY BY THE ADMINISTRATION OF Δ5-ANDROSTENE-3β-OL-7,17-DIONE AND 3β ESTERS THEREOF |
| 04/27/2000 | WO2000023079A1 Oral pharmaceutical compositions containing buprenorphin |
| 04/27/2000 | WO2000023077A1 Method for treating schizophrenia and means used in said method |
| 04/27/2000 | WO2000023076A1 Aminophenoxyacetic acid derivatives as neuroprotectants |
| 04/27/2000 | WO2000023067A1 Method for the treatment of mania and bipolar disorder |
| 04/27/2000 | WO2000023059A2 Use of anticonvulsant derivatives for treating alcohol dependency |
| 04/27/2000 | WO2000023057A2 Atypical antiphsychotic in combination with acetylcholinesterase inhibitor for improving cognition |
| 04/27/2000 | WO2000023055A1 Oral pulsed dose drug delivery system |
| 04/27/2000 | WO2000023053A2 Artificial antigen-specific cells and related methods |
| 04/27/2000 | WO2000023045A1 Pharmaceutical composition with gastric residence and controlled release |
| 04/27/2000 | WO2000022937A1 Protein material for slow digestion and its use |
| 04/27/2000 | WO2000006137A3 Glucocorticoid-selective anti-inflammatory agents |
| 04/27/2000 | WO2000005407A3 DUPLICATIONS OF HUMAN CHROMOSOME 15q24-25 AND ANXIETY DISORDERS, DIAGNOSTIC METHODS FOR THEIR DETECTION |
| 04/27/2000 | WO2000004895A3 Nutritional and therapeutic uses of 3-hydroxyalkanoate oligomers |
| 04/27/2000 | WO1999063933A9 Multivalent agonists, partial agonists and antagonists of the gaba receptors |
| 04/27/2000 | DE19856210A1 Use of thiol compound selected from oxidoreductase and/or hydrolase for treatment of chronic and acute tinnitus |
| 04/27/2000 | DE19849073A1 Transgene encoding amyloid precursor protein or its fragment, used to produce transgenic nematodes used, e.g. to screen for agents for treating Alzheimer's disease |
| 04/27/2000 | DE19849044A1 New polycythemia rubra vera-related polypeptide useful for diagnosis and for developing therapeutic antibodies |
| 04/27/2000 | CA2347792A1 (substituted)acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases |
| 04/27/2000 | CA2347172A1 Protein material for slow digestion and its use |
| 04/27/2000 | CA2347080A1 Tnfr related gene 12 |
| 04/27/2000 | CA2346937A1 Specific therapeutic interventions obtained by interference with redistribution and/or targeting |
| 04/27/2000 | CA2346436A1 N-(imidazolylalkyl)substituted cyclic amines as histamine-h3 agonists or antagonists |
| 04/27/2000 | CA2345767A1 Therapy for improving cognition |
| 04/27/2000 | CA2344677A1 Improving memory by the administration of .delta.5-androstene-3.beta.-ol-7,17-dione and 3.beta. esters thereof |
| 04/27/2000 | CA2341855A1 Method for treating schizophrenia, and means for use in this method |
| 04/27/2000 | CA2267488A1 Weight control product and method of treating hyperlipidemia and increasing vigor with said product |
| 04/26/2000 | EP0995751A2 Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction |
| 04/26/2000 | EP0995750A1 Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction |
| 04/26/2000 | EP0995743A1 Derivatives of dihydro- and tetrahydrochinoline as a medicinal antioxydans |
| 04/26/2000 | EP0995436A2 Ligands for sigma receptors and their therapeutical applications |
| 04/26/2000 | EP0995118A1 Chaperone fragments |
| 04/26/2000 | EP0994903A1 Methods and compositions for galactosylated glycoproteins |
| 04/26/2000 | EP0994902A1 Cyclic crf antagonist peptides |
| 04/26/2000 | EP0994900A1 Semaphorin receptors |
| 04/26/2000 | EP0994895A1 Dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 04/26/2000 | EP0994877A1 Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders |
| 04/26/2000 | EP0994876A1 Quaternary ammonium compounds as tachykinin antagonists |
| 04/26/2000 | EP0994875A1 3-pyridyl-1-aza-bicyclo-alkane derivatives for prevention and treatment of cns disorders |
| 04/26/2000 | EP0994873A1 Substituted 1h-pyridinyl-2-ones as gaba a?alpha 2/3 ligands |
| 04/26/2000 | EP0994872A1 4-phenylpiperidine compounds |
| 04/26/2000 | EP0994870A1 Novel aryloxy substituted pyrimidine imidazole compounds |
| 04/26/2000 | EP0994869A1 5-(2-ETHYL-2$i(H)-TETRAZOL-5-Y1)-1-METHYL-1,2,3,6-TETRAHYDROPYRIDINE MALEATE |
| 04/26/2000 | EP0994867A1 Polymorphic form of the tachykinin receptor antagonist 2-(r)-(1-(r) -(3,5-bis(trifluoromethyl) phenyl)ethoxy)-3-(s)-(4-fluoro) phenyl-4-(3-5 (-oxo-1h,4h-1,2,4,-triazolo) methylmorpholine |
| 04/26/2000 | EP0994866A1 5-(3-phenyl-3-oxo-propyl)-1h-tetrazole derivatives |
| 04/26/2000 | EP0994865A1 Triazole compounds and the use thereof as dopamine-d 3?-ligands |
| 04/26/2000 | EP0994864A1 Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
| 04/26/2000 | EP0994863A1 Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
| 04/26/2000 | EP0994862A2 Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation |
| 04/26/2000 | EP0994861A1 NEW $g(b)-AMINO AND $g(b)-AZIDOCARBOXYLIC ACID DERIVATIVES, THE PRODUCTION THEREOF AND THE USE THEREOF AS ENDOTHELIN RECEPTOR ANTAGONISTS |
| 04/26/2000 | EP0994860A1 Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists |
| 04/26/2000 | EP0994859A1 Compounds |
| 04/26/2000 | EP0994728A1 Recombinant antibodies specific for beta-amyloid ends, dna encoding and methods of use thereof |
| 04/26/2000 | EP0994710A1 Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin |
| 04/26/2000 | EP0994705A1 Therapeutic and dietary compositions containing essential fatty acids and bioactive disulphides |
| 04/26/2000 | EP0994703A2 Composition comprising ketanserin and l-carnitine or an alkanoyl l-carnitine for the treatment of crps |
| 04/26/2000 | EP0777671B1 Spiro-azabicyclic compounds useful in therapy |
| 04/26/2000 | EP0736020B1 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists |
| 04/26/2000 | EP0670826B1 Fatty acid derivatives and pharmaceutical compositions containing them |
| 04/26/2000 | EP0626853B1 Use of substituted adenine derivatives for treating multiple sclerosis |